Cargando…

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach

Detalles Bibliográficos
Autores principales:	Pugliese, Giusj Monia, Venafra, Veronica, Bica, Valeria, Massacci, Giorgia, Latini, Sara, Graziosi, Simone, Fischer, Thomas, Mougiakakos, Dimitrios, Boettcher, Martin, Perfetto, Livia, Sacco, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169656/ https://www.ncbi.nlm.nih.gov/pubmed/36966261 http://dx.doi.org/10.1038/s41375-023-01881-5

Ejemplares similares

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients
por: Massacci, Giorgia, et al.
Publicado: (2022)

P445: A SYSTEMS-BASED APPROACH TO UNVEIL DRUG RESISTANCE IN FLT3-ITD AML
por: Sacco, Francesca, et al.
Publicado: (2023)

Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance
por: Pugliese, Giusj Monia, et al.
Publicado: (2021)

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
por: Minetto, Paola, et al.
Publicado: (2020)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

A Resource for the Network Representation of Cell Perturbations Caused by SARS-CoV-2 Infection
por: Perfetto, Livia, et al.
Publicado: (2021)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

The Cyclin-dependent kinase 1: more than a cell cycle regulator
por: Massacci, Giorgia, et al.
Publicado: (2023)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2021)

Evaluation of FLT3-ITD Mutations and MDR1 Gene Expression in AML Patients
por: Yazdandoust, Ehsan, et al.
Publicado: (2022)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022)

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
por: Bogdanov, Konstantin, et al.
Publicado: (2023)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation
por: Tsitsipatis, Dimitrios, et al.
Publicado: (2017)

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
por: Stirewalt, D L, et al.
Publicado: (2014)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
por: Ha, You Na, et al.
Publicado: (2020)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD(+) AML Cells
por: Feng, Panpan, et al.
Publicado: (2022)

Hsa_circ_0015278 Regulates FLT3-ITD AML Progression via Ferroptosis-Related Genes
por: Jiang, Jiquan, et al.
Publicado: (2022)

Prognostication refinement in NPM1‐mutated acute myeloid leukemia stratified by FLT3‐ITD status with different induction doses of cytarabine
por: Wang, Biao, et al.
Publicado: (2023)

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
por: Sportoletti, Paolo, et al.
Publicado: (2019)

Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib
por: Ko, Ya-Chen, et al.
Publicado: (2019)

Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?
por: Kim, Hee-Je
Publicado: (2010)

Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML
por: Moloney, Jennifer N., et al.
Publicado: (2017)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
por: Kannan, Sankaranarayan, et al.
Publicado: (2022)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth
por: Coleman, Daniel J.L., et al.
Publicado: (2023)

携带ASXL1突变干细胞在供受者体内分别发展为FLT3-ITD阳性AML-M(2)及FLT3-ITD阴性AML-M(5)一例报告并文献复习
Publicado: (2019)

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients
por: Zuffa, Elisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uop2r99mv0gukk95lftjdratjo